Efficacy of SGLT2 inhibitors as additional treatment in Japanese type 2 diabetic patients: second or third choice?
Abstract Objectives Due to the increase of type 2 diabetes (T2D), the number of patients in treatment with multiple anti-diabetic agents is increased. According to the recent recommendation of treatment guidelines, sodium-glucose cotransporter 2 (SGLT2) inhibitors would be used as additional treatme...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-03-01
|
| Series: | BMC Research Notes |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13104-022-06010-6 |
| _version_ | 1811311653137940480 |
|---|---|
| author | Makoto Fujiwara Masaru Shimizu Yuko Maejima Kenju Shimomura |
| author_facet | Makoto Fujiwara Masaru Shimizu Yuko Maejima Kenju Shimomura |
| author_sort | Makoto Fujiwara |
| collection | DOAJ |
| description | Abstract Objectives Due to the increase of type 2 diabetes (T2D), the number of patients in treatment with multiple anti-diabetic agents is increased. According to the recent recommendation of treatment guidelines, sodium-glucose cotransporter 2 (SGLT2) inhibitors would be used as additional treatment to the currently administered anti-diabetic drugs for poorly controlled T2D patients. Here, we assessed the efficacy of SGLT2 inhibitors added to the current treatment with metformin, dipeptidyl peptidase-4 (DPP4) inhibitors, or both in Japanese T2D patients. Results Japanese T2D subjects with poor glucose control, who were treated with metformin (n = 10), DPP4 inhibitors (n = 11), or both (n = 28) and who were in need of additional treatment, were recruited. HbA1c levels before and 6 months after addition of SGLT2 inhibitor treatment were used to compare the effectiveness. The HbA1c levels after addition of SGLT2 inhibitors significantly decreased in all groups. The change in HbA1c levels (delta HbA1c) showed no significant difference between the three groups. The present data indicated that addition of SGLT2 inhibitors to metformin and/or DPP4 inhibitors is equally effective in the treatment of Japanese T2D patients. |
| first_indexed | 2024-04-13T10:22:37Z |
| format | Article |
| id | doaj.art-234d8ac6a58d434491dd260102086da1 |
| institution | Directory Open Access Journal |
| issn | 1756-0500 |
| language | English |
| last_indexed | 2024-04-13T10:22:37Z |
| publishDate | 2022-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Research Notes |
| spelling | doaj.art-234d8ac6a58d434491dd260102086da12022-12-22T02:50:27ZengBMCBMC Research Notes1756-05002022-03-011511410.1186/s13104-022-06010-6Efficacy of SGLT2 inhibitors as additional treatment in Japanese type 2 diabetic patients: second or third choice?Makoto Fujiwara0Masaru Shimizu1Yuko Maejima2Kenju Shimomura3Department of Diabetes, Endocrinology and Metabolism, Tsukuba Medical CenterDepartment of Bioregulation and Pharmacological Medicine, Fukushima Medical University School of MedicineDepartment of Bioregulation and Pharmacological Medicine, Fukushima Medical University School of MedicineDepartment of Bioregulation and Pharmacological Medicine, Fukushima Medical University School of MedicineAbstract Objectives Due to the increase of type 2 diabetes (T2D), the number of patients in treatment with multiple anti-diabetic agents is increased. According to the recent recommendation of treatment guidelines, sodium-glucose cotransporter 2 (SGLT2) inhibitors would be used as additional treatment to the currently administered anti-diabetic drugs for poorly controlled T2D patients. Here, we assessed the efficacy of SGLT2 inhibitors added to the current treatment with metformin, dipeptidyl peptidase-4 (DPP4) inhibitors, or both in Japanese T2D patients. Results Japanese T2D subjects with poor glucose control, who were treated with metformin (n = 10), DPP4 inhibitors (n = 11), or both (n = 28) and who were in need of additional treatment, were recruited. HbA1c levels before and 6 months after addition of SGLT2 inhibitor treatment were used to compare the effectiveness. The HbA1c levels after addition of SGLT2 inhibitors significantly decreased in all groups. The change in HbA1c levels (delta HbA1c) showed no significant difference between the three groups. The present data indicated that addition of SGLT2 inhibitors to metformin and/or DPP4 inhibitors is equally effective in the treatment of Japanese T2D patients.https://doi.org/10.1186/s13104-022-06010-6SGLT2 inhibitorsHbA1cMetforminDPP4 inhibitor |
| spellingShingle | Makoto Fujiwara Masaru Shimizu Yuko Maejima Kenju Shimomura Efficacy of SGLT2 inhibitors as additional treatment in Japanese type 2 diabetic patients: second or third choice? BMC Research Notes SGLT2 inhibitors HbA1c Metformin DPP4 inhibitor |
| title | Efficacy of SGLT2 inhibitors as additional treatment in Japanese type 2 diabetic patients: second or third choice? |
| title_full | Efficacy of SGLT2 inhibitors as additional treatment in Japanese type 2 diabetic patients: second or third choice? |
| title_fullStr | Efficacy of SGLT2 inhibitors as additional treatment in Japanese type 2 diabetic patients: second or third choice? |
| title_full_unstemmed | Efficacy of SGLT2 inhibitors as additional treatment in Japanese type 2 diabetic patients: second or third choice? |
| title_short | Efficacy of SGLT2 inhibitors as additional treatment in Japanese type 2 diabetic patients: second or third choice? |
| title_sort | efficacy of sglt2 inhibitors as additional treatment in japanese type 2 diabetic patients second or third choice |
| topic | SGLT2 inhibitors HbA1c Metformin DPP4 inhibitor |
| url | https://doi.org/10.1186/s13104-022-06010-6 |
| work_keys_str_mv | AT makotofujiwara efficacyofsglt2inhibitorsasadditionaltreatmentinjapanesetype2diabeticpatientssecondorthirdchoice AT masarushimizu efficacyofsglt2inhibitorsasadditionaltreatmentinjapanesetype2diabeticpatientssecondorthirdchoice AT yukomaejima efficacyofsglt2inhibitorsasadditionaltreatmentinjapanesetype2diabeticpatientssecondorthirdchoice AT kenjushimomura efficacyofsglt2inhibitorsasadditionaltreatmentinjapanesetype2diabeticpatientssecondorthirdchoice |